AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01504659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flat tonic water (e.g., Canada Dry Tonic Water)
Description: Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
Study NCT01766154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
Study NCT03194958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Quitline
Description: Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
Study NCT00649727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride ER Tablets 10 mg
Description: 2x10mg, single dose fed
Study NCT00649727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 10 mg
Description: 2x10mg, single dose fed
Study NCT02443545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Study NCT00892281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxycycline (Oracea®) 40 mg modified release as monotherapy
Description: Take once daily in the morning
Study NCT00892281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxycycline (Oracea®) 40 mg modified release as add-on therapy
Description: Take once daily in the morning
Study NCT03703024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry Leaf Extract
Description: Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
Study NCT03703024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered in a capsule
Study NCT03243929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Translation of District Sun Safe Policies to Schools
Description: Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
Study NCT03243929 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
Study NCT02217696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized reading training
Study NCT00412737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
Study NCT00412737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
Study NCT00708357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NG-monomethyl-L-arginine
Description: intravenous administration, bolus over 5 minutes, dosage 6mg/kg
Study NCT02268383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
Study NCT03158064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg by IV
Study NCT03158064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg by IV~\*300mg
Study NCT03194958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Needs Navigator
Description: Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
Study NCT04426890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: Prefilled syringe (PFS) of 1 mL solution
Study NCT03948308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample before, during and after infection treatment
Study NCT01642836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMM
Description: 1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions.
Study NCT01642836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Nutrition Education
Description: Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights
Study NCT01441115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT04426890 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: Prefilled syringe (PFS) of 1 mL solution
Study NCT04086966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-PET/MRI or PET/CT
Description: \[68Ga\]PSMA-PET/MRI or PET/CT
Study NCT03552016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Riboflavin
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
Study NCT03552016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Riboflavin
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
Study NCT02070549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT01402830 — intervention group
Intervention type: OTHER
Intervention: Visual analogue scales (EVAs)
Description: This scale measures the pain intensity.
Study NCT03934866 — intervention group
Intervention type: RADIATION
Intervention: Low Dose CT scan
Description: Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
Study NCT04436614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement:Aloe Vera with Crocus (saffron)
Description: Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
Study NCT04623541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
Study NCT04623541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
Study NCT04623541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Description: R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
Study NCT04623541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
Study NCT04436614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement:Aloe Vera (simple)
Description: Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
Study NCT04436614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Supplement:Mediterranean Diet
Description: Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
Study NCT02301208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin combine with IMRT
Study NCT02301208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin combine with IMRT
Study NCT01441115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI301
Study NCT00388661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin tablet 3 mg once daily
Description: Melatonin tablet 3 mg once daily
Study NCT04623541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days.
Study NCT04623541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
Study NCT00388661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study NCT04098263 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
Study NCT01368198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance Lubricating Eye Drops
Description: One instillation of the eye drop in each eye
Study NCT01368198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVE™
Description: One instillation of the eye drop in each eye
Study NCT01782794 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
Study NCT00306774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: 2,000 IU vitamin D capsule per day for 2 years
Study NCT00595790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Study NCT04324333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital wearable system
Description: Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
Study NCT00306774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule per day for 2 years
Study NCT01845259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Once a day 1,8 mg subcutaneous injection for 16 weeks
Study NCT03230162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
Study NCT03230162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
Study NCT01951248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP - continuous airway pressure
Description: 3 months of treatment with CPAP treatment
Study NCT04098263 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
Study NCT02948439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Brisk walking 3-4 times per week for up to 40 minutes of activity.
Study NCT05182918 — intervention group
Intervention type: OTHER
Intervention: Substance use disorder treatment
Description: The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
Study NCT04117633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Laparoscopic Procedures for Rectopexy
Study NCT03834896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AYMES MADRID
Description: AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
Study NCT02096107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
Study NCT02096107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Tacrolimus, mycophenolate mofetil and steroids
Study NCT03098095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Moderate physical activity
Study NCT01845259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide Placebo
Description: Once a day 1,8 mg subcutaneous injection for 16 weeks
Study NCT04374916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premaquick®
Description: Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
Study NCT04374916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARTOSURE®
Description: An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
Study NCT01699152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules
Study NCT02807493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Support Device
Description: Bite plate
Study NCT02807493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group
Study NCT03993704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHF-535
Description: Oral suspension administered once daily for 14 days
Study NCT03993704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHF-535
Description: Oral suspension administered once daily for 14 days
Study NCT01848860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesh coverage of the staple line
Description: Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
Study NCT03673046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
Description: 12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study NCT03673046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
Description: 12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study NCT00717093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Study NCT00717093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Study NCT02428270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: Small molecule inhibitor of focal adhesion kinase (FAK)
Study NCT02428270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
Study NCT04340778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal dinoprostone
Description: vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
Study NCT04340778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-prilocaine Cream
Description: Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Study NCT00026234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given intra-arterially
Study NCT00026234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intra-arterially
Study NCT00026234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00026234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT02403024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InterWalk
Description: Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
Study NCT02403024 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control
Description: Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks